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Abstract The VPAC2 (vasoactive intestinal peptide (VIP)2)
receptor is a seven-transmembrane spanning G protein-coupled
receptor which responds similarly to VIP and pituitary adenylate
cyclase activating polypeptide (PACAP) in stimulating cAMP
production. Recently, we reported the localisation of the human
VPAC2 receptor gene (VIPR2) to chromosome 7q36.3 (Mackay,
M. et al. (1996) Genomics 37, 345^353). Here, we describe the
characterisation of the VIPR2 gene structure and promoter
region. The VIPR2 gene is encoded by 13 exons, the initiator
codon of the 438 amino acid open reading frame is located in
exon 1 and the termination signal and a poly-adenylation signal
sequence are located in exon 13. The 5P untranslated region
extends 187 bp upstream of the initiator codon and is extremely
GC-rich (80%). The poly-adenylation signal is located 2416 bp
downstream of the stop codon. Intron sizes range from 68 bp
(intron 11) to 45 kb (intron 4) and the human gene spans 117 kb.
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1. Introduction
The 28 amino acid vasoactive intestinal peptide (VIP) and
the 38 amino acid pituitary adenylate cyclase activating poly-
peptide (PACAP) belong to a family of structurally related
hormones which include secretin, growth hormone releasing
hormone (GHRH), glucagon and glucagon-like peptide. The
action of these hormones is mediated through receptors which
belong to the group II family of seven-transmembrane G pro-
tein-coupled receptors ¢rst de¢ned by cloning of the rat secre-
tin, porcine calcitonin and opossum parathyroid hormone
(PTH) receptors [2]. Receptors which are members of this
family couple to adenylyl cyclase stimulation. Two distinct
receptors which respond equally to VIP and PACAP have
been cloned, the VPAC1 and the VPAC2 receptors [3^5].
Only 50% of their amino acid sequences are conserved, with
the greatest identity in the transmembrane spanning domains.
Both receptors are similarly related to the secretin [6] and the
PACAP (PAC1) [7,8] receptors. The VPAC1 receptor is ex-
pressed in liver, intestine and in the brain in cortex, hippo-
campus, cerebellum and olfactory bulb [3,9]. The VPAC2 re-
ceptor is expressed in the olfactory bulb, thalamus,
hippocampus and hypothalamus, particularly in the supra-
chiasmatic nucleus [4,9,10], as well as in the pancreas, heart,
stomach, lung and digestive tract [9,11]. The VPAC1 and
VPAC2 receptors have been mapped to human chromosomal
regions 3p22 [12] and 7q36.3 [1], respectively.
The human VPAC2 receptor cDNA was cloned originally
from a SUPT1 lymphoblastic cell line cDNA library [13]. We
report here the characterisation of the structure of the human
VIPR2 gene encoding the VPAC2 receptor. The 5P and 3P
untranslated regions (UTR) of the transcript have been deter-
mined by 5P and 3P rapid ampli¢cation of cDNA ends
(RACE) of a human placental cDNA library with receptor
speci¢c primers. An additional 2.7 kb of the genomic 5P £ank-
ing region has been sequenced and a number of consensus
binding sites for transcription factors which may be involved
in the regulation of VIPR2 gene expression have been identi-
¢ed.
2. Materials and methods
2.1. Drugs and chemicals
Standard laboratory chemicals of Analar grade were obtained from
Sigma or BDH Chemicals (Poole, UK). Oligonucleotide primers were
obtained from Cruachem (Glasgow, UK), Oswell DNA Service
(Edinburgh, UK) and Life Technologies (Paisley, UK).
2.2. Ampli¢cation of human VPAC2 receptor from the human SUPT1
cell line
Total RNA was isolated using Catriomox-14 surfactant reagent
(VH BIO, Newcastle-upon-Tyne, UK) from human SUPT1 cells (ob-
tained from the European Collection of Animal Cell Culture,
ECACC) which were grown in suspension. First strand cDNA was
synthesised from 1 Wg total RNA primed with random hexamers using
SuperScript II reverse transcriptase (Life Technologies). Ampli¢cation
of ¢rst strand cDNA for 35 cycles with the VPAC2 receptor speci¢c
primers 6247 (5P-GGGGGACCTAGGACGGAG-3P) and 4334 (5P-
CCAGGTATGGGGTTTAGTGGAC-3P) and Pfu polymerase (Stra-
tagene, Cambridge, UK) resulted in a 1.54 kb product which was gel-
puri¢ed and ligated into the pGEM-T vector (Promega, Southamp-
ton, UK) and several clones were selected and sequenced in both
directions.
2.3. Anchored 5P and 3P RACE for the human VPAC2 receptor cDNA
An anchored cDNA library was synthesised from human placental
poly-A RNA using the Marathon cDNA Ampli¢cation kit (Clon-
tech Laboratories, Basingstoke, Hampshire, UK). The 5P end of the
human VPAC2 receptor was ampli¢ed using touchdown PCR condi-
tions and 35 cycles with the Clontech anchor primer, AP1, and the
human VPAC2 receptor speci¢c primer 19076 (5P-AGGCAG-
CAGCGTCCGCATCCCGAG-3P), with Advantage KlenTaq Poly-
merase Mix (Clontech). Ampli¢cation products were checked by gel
electrophoresis. The ¢rst round of ampli¢cation reaction was then
diluted 1:100 Wl with sterile H2O and a second round of PCR was
performed under the same conditions with 5 Wl of diluted ¢rst round
mix along with nested primers AP2 (Clontech) and the human VPAC2
receptor speci¢c primer EO5 (5P-GAGCGAGTGCGCGGAGACCT-
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3P). Ampli¢cation products were size-selected by gel electrophoresis,
subcloned into the pGEM-T Easy vector (Promega) and sequenced in
both directions. The 3P end of the VPAC2 receptor was similarly
ampli¢ed from anchored human placental cDNA, with primers AP1
and the human VPAC2 receptor speci¢c primer 32199 (5P-
TGCCCTGGTGGGTCATACGAA-3P) (for the ¢rst round of ampli-
¢cation) and with AP2 and the human VPAC2 receptor speci¢c
primer 32200 (5P-AGCTGGTTGTCCACTAAACCCCAT-3P) (for
the second round). The 2.3 kb PCR product was gel-puri¢ed and
subcloned into the pGEM-T Easy vector and several clones were
selected and sequenced in both directions.
2.4. Isolation of human genomic clones
A gridded human genomic DNA library RPCI1 (obtained from the
UK MRC HGMP Resource Centre), constructed in the P1-PAC clon-
ing vector pCYPAC2 [14], was screened with the full length human
VPAC2 receptor cDNA and with a 140 bp PCR fragment ampli¢ed
from the cDNA with the exon 5 primer 9047 (5P-TCTGGT-
GAAGGCCATTTATACCC-3P) and exon 6 primer HO4 (5P-CTC-
AGGATGAAGGACAGGAACAGG-3P). The cDNA probes were la-
belled with [K-32P]dCTP (3300 mCi/mmol, NEN Life Science
Products, Hounslow, UK) using Ready-To-Go DNA labelling beads
(Amersham Pharmacia Biotech UK, Little Chalfont, Buckingham-
shire, UK). Filters were hybridised at 45‡C overnight in a bu¡er
containing 50% formamide, 6USSC (1USSC = 0.15 M NaCl, 0.015
M sodium citrate, pH 7.0), 5UDenhardt’s solution, 0.5% SDS and
100 Wg/ml sheared herring sperm DNA. After hybridisation, ¢lters
were washed at 65‡C in 0.5USSC, 0.5% SDS, 1 mM EDTA and
exposed to Fuji RX autoradiography ¢lm. Positive clones were ob-
tained from the UK MRC HGMP Resource Centre. Isolation of
YAC clones HSC7E526 and E145A7 and cosmid clones 14, 126g6,
66e9, 122e11, 79g3 and 164g2 were as described by Mackay [1] and
Shen et al. (in preparation).
Genomic BamHI fragments were extracted from agarose gels with
the QiaexII gel extraction kit (Qiagen, Crawley, UK), subcloned into
pGEM11z (Promega) and sequenced with exon speci¢c primers. In-
tron sizes were con¢rmed by PCR using human genomic DNA
(Boehringer Mannheim, Lewes, UK), exon speci¢c primers and the
Expand Long Template PCR kit (Boehringer Mannheim) according
to the manufacturer’s instructions. Southern blots to detect the long
YAC arm were as described by Shen et al. (in preparation).
3. Results
3.1. Characterisation of the human VPAC2 receptor cDNA
A single 1536 bp cDNA sequence encoding the VPAC2
receptor was isolated from reverse transcriptase PCR ampli¢-
cation with the primers 6247 and 4334 of RNA extracted from
the human lymphoblastic SUPT1 cell line (Fig. 1). The se-
quence of the cDNA contained an open reading frame
(ORF) encoding a 438 amino acid protein which includes
seven hydrophobic, putative transmembrane spanning do-
mains. The 5P and 3P ends of the transcript were determined
from 5P and 3P RACE fragments ampli¢ed from a human
placental cDNA library. Thirty overlapping fragments of var-
ious lengths were isolated and sequenced after ampli¢cation of
the 5P end. The sequence of the longest fragment extended 187
bp upstream of the ATG initiation codon. Ampli¢cation of
the 3P end by RACE resulted in one 2.3 kb sequence. The 3P
UTR extends 2473 bp downstream of the stop codon and
includes a poly-adenylation signal sequence 19 residues up-
stream of the poly-A tail (Fig. 1). The composite cDNA se-
quence length is 3974 bp.
The pentamer sequence AUUUA is found within the
VPAC2 receptor cDNA sequence, along with U-rich domains
and hairpin sequences. These have been implicated in the
destabilisation and agonist-induced downregulation of recep-
tor mRNA [15,16]. One AUUUA sequence is found in exon 5
(residues 385^389) and two in exon 13 in a region 190 bp
downstream of the stop codon. The U-rich domains along
with the hairpin sequence £ank these sequences within the
3P UTR.
3.2. The VIPR2 gene is comprised of 13 exons
In order to determine the structure of the VIPR2 gene,
various genomic clones contained in YAC, PAC and cosmid
vectors which hybridised with the VPAC2 receptor cDNA
were isolated. The YAC and cosmid clones have been de-
scribed previously [1]. The PAC clone 118F4 was isolated
from a gridded human genomic library after hybridisation
with the 1.54 kb VPAC2 receptor cDNA clone. A second
PAC clone, 228M22, was isolated after rescreening the library
with the 140 bp PCR fragment encoding exons 5 and 6 am-
pli¢ed from the human cDNA.
Intron sizes were determined by PCR ampli¢cation of hu-
man genomic DNA and Southern blot analysis of YAC, PAC
and cosmid genomic clones (Table 1). Oligonucleotide primers
were designed to amplify across putative exon boundaries
which were predicted by characterisation of the mouse gene
(Mackay et al., in preparation). Intron 4 was only partially
characterised as it was too large, or unstable, for ampli¢cation
and none of the PAC or cosmid clones spanned it. Intron 5
was ampli¢ed from human genomic DNA and PAC 228M22,
but was to large (15 kb) to subclone for restriction and se-
quence analysis. Therefore, a 12 kb BamHI fragment from
PAC 228 DNA which hybridised with the exon 5/6 PCR frag-
ment was excised from a gel and sequenced with exon 5 spe-
ci¢c primers. Table 1 and Fig. 1 show the location of exon
boundaries within the cDNA sequence.
Various BamHI fragments from the PAC and cosmid
clones, encoding exons 1, 2, 3-4, 6, 7-9 and 10-13, were sub-
cloned and exon/intron boundaries were determined by se-
quencing. Fig. 2a shows the arrangement of exons along
with a partial restriction map of the gene and position of
the PAC and cosmid clones. The amino-terminus of the re-
ceptor is encoded by the ¢rst ¢ve exons, the transmembrane
spanning domains by exons 5^12 and the carboxyl tail by
exon 13 (Fig. 2b). To date, we have found no evidence for
splice variants, or additional exons, for the VPAC2 receptor.
3.3. Human YAC clones containing the VIPR2 gene
The human VIPR2 gene was localised close to the telomere
of chromosome 7q [1] with the 5P end of the gene oriented
towards the telomere. The position of the VIPR2 gene and the
presence of various chromosome 7q36 markers were deter-
mined for the YAC clones HSC7E526 and E145A7 by PCR
analysis. Both the 550 kb YAC, HSC7E526, and the 200 kb
YAC, E145A7, span the entire gene, which is 117 kb. Further
characterisation of the YAC HSC7E526 by FISH suggested
C
Fig. 1. The 3974 bp sequence of the human VPAC2 receptor (accession number X95097) and protein translation of the ORF. The transmem-
brane spanning domains are highlighted. Exon boundaries are de¢ned by the symbol S. The arrows indicate the positions of the PCR primers
used to amplify the cDNA (black arrows), the 5P RACE (stippled arrows) and 3P RACE (hatched arrows) fragments. The VIPR2 gene se-
quence has been deposited in the database, accession numbers Y18423^Y18431.
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that the YAC is not chimeric (data not shown). Analysis of
the YAC HSC7E526 DNA with eight STS markers (D7S594,
SWSS2567, SWSS1117, SWSS225, SWSS2253, D7S68,
SWSS25 and SWSS3199) which span approximately 100 kb
intervals showed that the YAC encompasses ¢ve (SWSS2567,
SWSS1117, SWSS225, SWSS2253 and D7S68) of the markers
tested (Fig. 3).
The complete sequence of the terminal 226 kb of human 7q
telomere, including the entire VIPR2 promoter, exons 1 and 2,
intron 1 and 31.9 kb of intron 2, was made available recently
(accession number AF027390). This sequence indicates that
the distance between the telomeric marker D7S594 and
SWSS2567 is approximately 79 kb and the distance between
D7S594 and SWSS1117 (which is located in intron 2 of the
VIPR2 gene) is approximately 218 kb. Analysis of human
genomic DNA by PCR and by sequencing indicates that
SWSS1117 lies approximately 0.6 kb upstream from exon 3
(data not shown). Subsequently, the entire gene sequence has
been released (accession number AC007269), con¢rming the
location of the marker SWSS225 within intron 4. The distance
between exon 1 of the VIPR2 gene and the marker D7S594 is
184 kb. These ¢gures suggest that the YAC HSC7E526 (trun-
cated between markers D7S594 and SWSS2567) harbours
V105^180 kb of the 5P sequence, the entire VIPR2 gene
(117 kb) and V260^330 kb of the sequence downstream of
the gene.
3.4. The 5P promoter region is extremely GC-rich
The 5P promoter region was determined from the sequence
of two overlapping genomic clones, a 2.4 kb BamHI and a 3.2
Table 1
Table of exon/intron boundaries of the human VIPR2 gene
Exon boundaries Splice junctions Amino acid residue Intron size (kb)
Exon 1/2 GCCCCCgtgagt...gaacagGTGAAC Pro-17/Val-18 2.2
Exon 2/3 ACAAAGgtaagg...ttccagCCTGCA Ala-51 32.5
Exon 3/4 AAGCAGgtactg...tttcagGAAACA Gly-87 6.4
Exon 4/5 AGCAAGgtaggc...ttgtagATCACG Lys-94/Ile-95 45
Exon 5/6 CTTCAGgtaagg...cctcagGAAGCT Arg-152 15
Exon 6/7 TCCTGGgtaagg...ttccagGTGGGC Trp-199/Val-200 6
Exon 7/8 GATGGGgtaagt...ctgcagGCCTCC Gly-250 1.1
Exon 8/9 CACCGGgtgagt...tgacagTTGCTG Gly-270 1.2
Exon 9/10 ATCATCgtaaag...gtgcagGTCAAT Ile-293/Val-294 0.276
Exon 10/11 GTACAAgtgagt...gtgcagGAGGCT Lys-324 2.1
Exon 11/12 TTCCAGgtaggt...ttgcagGGCCTG Gln-367/Gly-368 0.068
Exon 12/13 AGTGAGgtaagt...tcacagGTGCAG Glu-381/Val-382 1.1
Fig. 2. (a) Partial restriction map of the human gene which includes sites for EcoRI (R), XhoI (X), NotI (N) and BamHI (B). The positions of
YAC, PAC and cosmid clones are shown. Arrow heads indicate where genomic clones extend beyond the mapped region. Exons are indicated
by the vertical lines and are numbered 1^13. The hash marks in intron 4 indicate the uncharacterised region. (b) Structure of the 3974 bp
cDNA with the positions of exon boundaries indicated by lines descending from the exon regions marked in (a). The transmembrane spanning
domains are indicated by the black boxes within the coding region, £anked by the ATG and TAG sequences. The position of the poly-adenyla-
tion signal is indicated by the AATAAA sequence.
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kb PstI fragment subcloned from cosmid 14, which included
the ATG initiation codon (exon 1), the 5P £anking sequence
and part of intron 1. Identi¢cation of transcription factor sites
was performed using the TESS-String-based Search computer
program2. Fig. 4 shows part of the 5P £anking sequence, along
with the start of the longest 5P RACE product (used to de¢ne
the 5P boundary of exon 1) and location of transcription fac-
tor sites which may be involved in regulating expression of the
VIPR2 gene. Primer extension was tried to determine the ex-
act location of the transcription start site, but was not suc-
cessful perhaps due to the high GC content of the 5P UTR
(80%). The GC content of the 5P £anking sequence extending
850 bp upstream of the 5P RACE product is approximately
71%.
No TATA-box was found in the GC-rich region upstream
of the putative 5P boundary of exon 1. Within the GC-rich
region are several sites for the transcription factor Sp1 [17].
Immediately upstream of the GC-rich region is a 1.35 kb
region which contains multiple repeats of the sequences CA-
GATAG (14 repeats) and GATGATAG (25 repeats) which
are potential sites for the GATA family of transcription fac-
tors [18].
4. Discussion
In this study, we have characterised the gene structure of
the human VPAC2 receptor and de¢ned the 5P and 3P ends of
the cDNA. The 3974 bp cDNA sequence was determined
from a composite which included the sequences of the 5P
and 3P RACE products. The size of the human transcript
has previously been determined by Northern blot analysis as
two hybridising bands at 4.6 and 2.3 kb [19]. The presence of
AUUUA pentamer sequences and U-rich regions within the
coding sequence and 3P UTR provides evidence for post-tran-
scriptional regulation of the mRNA [20]. These regions have
been shown to be important for protein binding to the 5-HT2c
receptor mRNA [16] and are involved in agonist induced de-
stabilisation of the L-adrenergic receptor mRNA [15]. Similar
regions are found within the calcitonin receptor mRNA [21].
We were unable to determine the exact start of transcription
for the VIPR2 gene. Some members of the secretin receptor
family have multiple exons encoding the 5P UTR [21^24].
However, this does not appear to be the case for the VPAC2
receptor. The 5P UTR (determined from the 5P RACE prod-
uct) and the translational start site of the human gene are
encoded within the same exon. As with the mouse Vipr2
gene (Mackay et al., in preparation), this exon and the ge-
nomic sequence £anking it are extremely GC-rich. The human
exon is located within a 1.4 kb CpG island. Although there
are no TATA-box sequences near the 5P end of this exon,
there are several consensus binding sites for the transcription
factors Sp1 and MAZ, which have been shown to be impor-
tant for transcription of the 5-HT1a receptor gene which has a
TATA-less promoter region [25]. Promoter regions which are
GC-rich and contain Sp1 binding sites but not TATA sites
have been shown to be activated by Sp1 recruiting speci¢c co-
activators to bind TFIID [26,27]. The promoter regions which
have been characterised for genes of members of the secretin
receptor family typically do not have a TATA-box immedi-
ately upstream of the transcriptional start site and are ex-
tremely GC-rich [12,21,28^30]. Pei et al. [30] have shown
that Sp1 binds to the promoter and activates the rat Vipr1
gene. We are currently investigating whether a similar tran-
scription mechanism, involving Sp1 rather than TATA bind-
ing proteins, operates for the VIPR2 gene.
Multiple promoter regions have been described for PTH
and glucagon receptor genes. The PTH receptor gene has
been shown to be controlled by two promoters, one of which
is not GC-rich and is only active in kidney [31]. There is no
evidence that the VPAC2 receptor is controlled by more than
one promoter as only one type of 5P UTR has been found
with 5P RACE.
A number of putative binding sites for tissue speci¢c factors
are located within the genomic 5P £anking sequence. For in-
stance, a site for the transcription factor Pit-1A, which is
involved in activating gene expression in speci¢c pituitary
cell types [32], is found approximately 1 kb upstream of
exon 1. The VPAC2 receptor is expressed in the anterior pi-
tuitary and in clonal somatomammotroph cell lines [33]. Also
within this region are sites for the CAC binding protein [34]
and LyF-1 [35], further upstream of the VIPR2 exon 1 is a
region (between residues 31200 and 32550) which contains
multiple repeats and GATA sites [18]. These sites may be
involved in the di¡erential expression of the VPAC2 receptor
in lymphocytes [36].
Genes encoding receptors belonging to the secretin receptor
family are interrupted by several introns [12,21^23,31,37]. The
VIPR2 gene is composed of 13 exons, which are interrupted
Fig. 3. Physical map of the terminal region of human chromosome 7q36 and position of the VIPR2 gene contained within YAC clones
HSC7E526 and E145A7. The order of the DNA markers at the extreme end of 7q36 and their location relative to the gene are shown.
2 TESS: Transcription Element Search System on the World Wide
Web; Jonathan Schug and G. Christian Overton, Technical Report
CBIL-TR-1997-1001-v0.0 of the Computational Biology and Infor-
matics Laboratory, School of Medicine, University of Pennsylvania,
1997.
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by introns of varying length from 68 bp (intron 11) to 45 kb
(intron 4). This gene appears to be one of the largest genes in
this receptor family, spanning 117 kb. Other receptors belong-
ing to this family are alternatively spliced to generate various
isoforms of the receptor. The rat PAC1 receptor can be alter-
natively spliced in the 5P UTR [24], the amino-terminal ex-
tracellular domain [38] and the third intracellular loop (ic3)
[39]. The region encoding ic3 is interrupted by an intron which
contains two additional 84 bp exons (hip and hop) which give
rise to one of two 28 amino acid cassettes (hip and hop1), a 27
amino acid cassette (hop2), a 56 amino acid cassette (hiphop1)
or a 55 amino acid cassette (hiphop2) which may be spliced
into ic3 at amino acid residue L-348, giving rise to six iso-
forms of this receptor [39]. Similarly, the two exons encoding
the GHRH receptor ic3 are interrupted by an intron which
contains a 123 bp exon encoding a 41 amino acid cassette [40].
The long form of the GHRH receptor has this cassette in-
serted in ic3 at the same position as those of the PAC1 re-
ceptor. The human VPAC2 receptor ic3 is encoded by exons
10 and 11, which are interrupted by a 2.1 kb intron. We have
sequenced this intron (accession number Y18430) and have
found a number of consensus sequences conforming to the
GT-AG rule for exon/intron splice junctions [41]. However,
ampli¢cation of this region from cDNA made from various
tissues has not indicated the presence of other isoforms of the
VPAC2 receptor.
Fig. 4. Sequence of the 5P region £anking the translation start site within the ¢rst exon of the VIPR2 gene. The translation start site (in bold)
is numbered +1 and the sequence comprising the ¢rst exon is italicised. The symbol D marks the start of the longest 5P RACE product and
the boundary of exon 1. The position of the 3P end of the primer 19076 is marked with the symbol P and the primer EO5 with the symbol
S. Putative transcription factor binding sites in the promoter region are labelled above the sequence. The GATA site sequences are underlined.
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In summary, we have described the 5P and 3P ends of the
human VPAC2 receptor cDNA and characterised the exon/
intron organisation of the VIPR2 gene. In addition, we have
identi¢ed several putative regulatory sites within a GC-rich
sequence £anking the 5P end of the ¢rst exon.
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